ID   BT-12
AC   CVCL_M155
SY   BT12
DR   BioSample; SAMN10989598
DR   CCLE; BT12_SOFT_TISSUE
DR   Cell_Model_Passport; SIDM01514
DR   DepMap; ACH-000160
DR   PharmacoDB; BT12_113_2019
DR   Wikidata; Q54798448
RX   PubMed=17446062;
RX   PubMed=20922763;
RX   PubMed=31068700;
WW   http://www.cogcell.org/dl/BrainTumorDataSheets/BT-12_Cell_Line_Data_Sheet_COGcell_org.pdf
WW   http://www.cogcell.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   From: Biegel J.; Children's Hospital of Philadelphia; Philadelphia; USA.
CC   Doubling time: 27 hours (PubMed=20922763).
CC   Omics: Deep exome analysis.
ST   Source(s): COG; PubMed=20922763
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D18S51: 13,14
ST   D19S433: 12,14
ST   D21S11: 29,33.2
ST   D2S1338: 23
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 13,15
ST   FGA: 22
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C6906; Atypical teratoid/rhabdoid tumor
DI   ORDO; Orphanet_99966; Atypical teratoid rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   2M
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 12-03-20; Version: 13
//
RX   PubMed=17446062; DOI=10.1016/j.ejca.2007.03.003;
RA   D'cunja J., Shalaby T., Rivera P., von Buren A., Patti R.,
RA   Heppner F.L., Arcaro A., Rorke-Adams L.B., Phillips P.C.,
RA   Grotzer M.A.;
RT   "Antisense treatment of IGF-IR induces apoptosis and enhances
RT   chemosensitivity in central nervous system atypical teratoid/rhabdoid
RT   tumours cells.";
RL   Eur. J. Cancer 43:1581-1589(2007).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//